argenx SE (ARGX)
NASDAQ: ARGX · IEX Real-Time Price · USD
372.80
+4.20 (1.14%)
Apr 26, 2024, 4:00 PM EDT - Market closed
argenx SE Revenue
In the year 2023, argenx SE had annual revenue of $39.48M with 270.16% growth.
Revenue (ttm)
$39.48M
Revenue Growth
+270.16%
P/S Ratio
561.18
Revenue / Employee
$34,391
Employees
1,148
Market Cap
22.16B USD
Revenue Chart
* The company reports in EUR currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 39.48M | 28.82M | 270.16% |
Dec 31, 2022 | 10.67M | -554.42M | -98.11% |
Dec 31, 2021 | 565.09M | 514.79M | 1,023.52% |
Dec 31, 2020 | 50.30M | -37.86M | -42.95% |
Dec 31, 2019 | 88.16M | 63.47M | 257.04% |
Dec 31, 2018 | 24.69M | -19.01M | -43.50% |
Dec 31, 2017 | 43.70M | 28.22M | 182.22% |
Dec 31, 2016 | 15.48M | 8.04M | 108.00% |
Dec 31, 2015 | 7.44M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Cardinal Health | 216.15B |
Molina Healthcare | 35.85B |
Baxter International | 14.81B |
ICON PLC | 8.23B |
Zimmer Biomet Holdings | 7.39B |
STERIS | 5.41B |
Illumina | 4.50B |
BioNTech SE | 4.24B |
ARGX News
- 11 days ago - argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease - GlobeNewsWire
- 4 weeks ago - argenx Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease - GlobeNewsWire
- 4 weeks ago - argenx Announces Annual General Meeting of Shareholders on May 7, 2024 - GlobeNewsWire
- 4 weeks ago - argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia - GlobeNewsWire
- 7 weeks ago - argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting - GlobeNewsWire
- 2 months ago - argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update - GlobeNewsWire
- 2 months ago - argenx to Present at Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024 - GlobeNewsWire